Importance of Surrogate Markers in Evaluation of Antiviral Therapy for HIV Infection

JAMA

Volumn 276, Issue 2, 1996, Pages 159-160

  Deyton, Lawrence ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG RESEARCH; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029683044     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.2.159     Document Type: Article

References (28)

1. Institute of Medicine. Surrogate Endpoints in Evaluating the Effectiveness of Drugs Against HIV Infections and AIDS. Washington, DC: National Academy Press; 1990.
2. Prentice RL. Surrogate endpoints in clinical trials. Stat Med. 1989;8:431-MO.
3. Fleming TR, Prentice EL, Pepe M, Glidden D. Surrogate and auxiliary endpoints in clinical trials with potential applications in cancer and AIDS research. Stat Med. 1994;13:955-968.
4. Freedman L, Graubard B, Schatzldn A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992;11:167-178.
5. Eyster ME, Ballard J, Gail M, et al. Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count. Ann Intern Med. 1989;110:963-969.
6. De Wolf F, Goudsmit J, Paul DA, et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenemia. BMJ. 1987;295:569-572.
7. DeGruttola V, Beckett LA, Coombs RW, et al. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. J Infect Dis. 1994;169:713-721.
8. Kappes J, Saag M, Shaw G, et al. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared. J Acquir Immune Deßc Syndr Hum Retrovirol. 1995;10:139-149.
9. Ho DD, Moudgil T, Alam M. Quantitäten of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989;321:1621-1625.
10. Coombs RW, Collier A, Allain J, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989;221:1626-1631.
11. Reichelderfer PS, Coombs R. Virologie parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation and validation. J Acquir Immune Dec Syndr Hum Retrovirol. 1995;10(suppl 2):S19-S24.
12. Hammer SM. Virologie markers and outcome in ACTG 175. In: Proceedings of the Third Conference on Retroviruses and Opportunistic Infections; January 30, 19%; Washington, DC. Abstract S24.
13. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988;239:617-622.
14. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992;165:352-363.
15. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993;118:674-680.
16. Lin D, Fischl M, Schoenfeld D. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med. 1993:12:835-842.
17. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med. 1994;13: 1423-1435.
18. Wei X, Ghosh S, Taylor M, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
19. Ho DD, Neumann A, Perelson S, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
20. Mellors JW, Kingsley L, Rinaldo C, et al. Quantitäten of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-579.
21. O'Brien WA, Hartigan P, Martin D, et al. Changes in plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996; 334:426431.
22. D'Aquila RT, Hughes M, Liou S. A comparative study of a combination of zidovudine, didanosine, and double-blinded nevirapine versus a combination of zidovudine and didanosine. In: Proceedings of the Second National Conference on Human Retroviruses and Related Infections; February 1,1995; Washington, DC. Abstract 384.
23. + cells per cubic millimeter. N Engl J Med. 1995;233:1662-1669.
24. Collier A, Coombs R, Schoenfeld D, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996; 334:1011-1017.
25. Thompson M, Ferez G, Baxter J, et al. CPCRA 036: HIV RNA Protocol. Bethesda, Md: National Institute of Allergy and Infectious Diseases, Division of AIDS; 1995.
26. Hughes MD, DeGruttola V, Wells S. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(suppl 2):S1-S8.
27. Gazzard B. Further results from European/Australian Delta Trial. In: Proceedings of the Third Conference on Retroviruses and Opportunistic Infections; February 1,1996; Washington, DC. Abstract LBSa.
28. Saravolatz L, Collins G, Hodges J, Winslow D. A randomized, comparative trial of ZDV vs ZDV plus ddl vs ZDV plus ddC in persons with CD4 cell counts of 200/ mm'. In: Proceedings of the Third Conference on Retroviruses and Opportunistic Infections; February 1, 1996; Washington, DC. Abstract LB4.